Griet Compernolle

Trough Concentrations of Infliximab Guide Dosing for Patients With Inflammatory Bowel Disease

Niels Vande Casteele, Marc Ferrante, Gert Van Assche et al. · Gastroenterology · 2015 · 859 citations

Trough Concentrations, Inflammation, Anti-inflammatory +5

Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel Diseases

Erwin Dreesen, Bram Verstockt, Sumin Bian et al. · Clinical Gastroenterology and Hepatology · 2018 · 153 citations

Inflammation, Support Monitoring, Functional Gastrointestinal Disorder +9

Prediction and Reduction of the Aggregation of Monoclonal Antibodies

Rob van der Kant, Anne R. Karow‐Zwick, Joost Van Durme et al. · Journal of Molecular Biology · 2017 · 144 citations · Full text

Withdrawal of Immunomodulators After Co-treatment Does Not Reduce Trough Level of Infliximab in Patients With Crohn’s Disease

David Drobne, Peter Bossuyt, Christine Breynaert et al. · Clinical Gastroenterology and Hepatology · 2014 · 131 citations

Inflammation, Chronic Inflammatory Diseases, Co-treatment Does +8

Ustekinumab Exposure-outcome Analysis in Crohn’s Disease Only in Part Explains Limited Endoscopic Remission Rates

Bram Verstockt, Erwin Dreesen, Maja Noman et al. · Journal of Crohn s and Colitis · 2019 · 118 citations · Full text